Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterization of tumor cell lines derived from genetically engineered mouse models of bladder cancer

ABSTRACT: We have generated various genetically engineered mouse models (GEMMs) of advanced bladder cancer that recapitulate various morphological variants of human tumors, with distinct histological characteristics, differing onset times or growth rates, and varying incidences of dissemination. To investigate the molecular pathways underlying these features, we performed a transcriptomic analysis of these models in comparison with control urothelium. Given that concurrent TP53 and RB1 alterations are frequently observed in human tumors and are associated with specific molecular subtypes and increased aggressiveness, this study aimed to develop and characterize new models comparing the combined loss of Pten, Trp53, and Rb1 (in an Rbl1-null background, due to functional compensation of Rb1 loss in mouse tissues) with the loss of Pten and Trp53 alone, where the retinoblastoma (Rb) family remains intact. In both models, basal urothelial cells were targeted using adenoviruses expressing Cre unther de control of the Krt5 promoter (Ad5-Krt5-Cre), while luminal urothelial cells were targeted using the murine Krt20 promoter (Ad5-Krt20-Cre). Despite the advantages offered by these GEMMs, their limitations—including unpredictable tumor onset, long latency periods, and difficulties in early tumor detection—led us to develop immunocompetent heterotopic models using tumor cell lines derived from primary tumors arising in GEMMs. These models enable more accurate tumor monitoring and synchronized growth, thereby improving the robustness of preclinical studies. Here, we provide a transcriptomic analysis of some of these bladder tumor-derived cells.

ORGANISM(S): Mus musculus

PROVIDER: GSE302079 | GEO | 2026/02/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genetically engineered mouse models and syngeneic graft models of bladder cancer

Project description:We have generated various genetically engineered mouse models (GEMMs) of advanced bladder that recapitulate various morphological variants of human tumors, with distinct histological characteristics, differing onset times or growth rates, and varying incidences of dissemination. To investigate the molecular pathways underlying these features, we performed a transcriptomic analysis of these models in comparison with control urothelium. Given that concurrent TP53 and RB1 alterations are frequently observed in human tumors and are associated with specific molecular subtypes and increased aggressiveness, this study aimed to develop and characterize new models comparing the combined loss of Pten, Trp53, and Rb1 (in an Rbl1-null background, due to functional compensation of Rb1 loss in mouse tissues) with the loss of Pten and Trp53 alone, where the retinoblastoma (Rb) family remains intact. In both models, basal urothelial cells were targeted using adenoviruses expressing Cre unther de control of the Krt5 promoter (Ad5-Krt5-Cre), while luminal urothelial cells were targeted using the murine Krt20 promoter (Ad5-Krt20-Cre). Despite the advantages offered by these GEMMs, their limitations—including unpredictable tumor onset, long latency periods, and difficulties in early tumor detection—led us to develop immunocompetent heterotopic models using tumor cell lines derived from primary tumors arising in GEMMs. These models enable more accurate tumor monitoring and synchronized growth, thereby improving the robustness of preclinical studies.

2026-02-25 | GSE295920 | GEO

Wide versus cell type restricted deletion of four tumor suppressor genes determines the type of high grade neuroendocrine lung cancer

Project description:Here we describe novel murine models of High Grade Neuroendocrine Lung Carcinomas driven by the loss of four tumor suppressors: deletion of Rb, PTEN, and p53, in a Rbl1 null background, in a wide variety of lung epithelial cells produces Large Cell Neuroendocrine Carcinoma whereas inactivation of these genes exclusively in basal cells leads to the development of Small Cell Lung Carcinoma, showing that Keratin K5 expressing cells contribute to the development/act as cell of origin of Small Cell Lung Carcinoma differentially influencing the lung cancer type developed. Conditional ablation of Rb1, Trp53 and Pten in pulmonary cells was achieved by intratracheal administration of purified Ad5-CMVcre or Ad5-K5cre (Du Page et al, 2009) to Rb1F/F;Trp53F/F;PtenF/F;Rbl1−/− 8–10 week old mice. Mice were sacrificed 3 to 5 months after the Ad5-cre infection and tumors processed for whole transcriptome analysis. As control animals, RbF/F;p53F/F;PtenF/F;Rbl1−/− littermates were used.

2019-10-15 | GSE121574 | GEO

Pten and p53 loss in the mouse lung causes adenocarcinoma and sarcomatoid carcinoma

Project description:Here we describe novel murine models of pulmonary adenocarcinoma (ADC) and sarcomatoid carcinoma (PSC) driven by the loss of two tumor suppressors: deletion of Trp53 and Pten. Combined deletion of Pten and Trp53 in the lungs of adult conditional mice leads to the development of both ADC and PSC irrespective of the lung targeted cell type or naphthalene induced airway epithelial regeneration. Although this model shows long latency periods and incomplete penetrance for tumor development, it is the first PSC mouse model reported so far, and sheds light on the relationships between ADC and PSC and their cells of origin. Moreover, human ADC show strong transcriptomic similarities to mouse PSC, providing a link between these tumor types and human ADC. Ablation of Trp53 and Pten in pulmonary cells was achieved by intratracheal administration of purified Ad5-CMVcre or Ad5-K5cre (Du Page et al, 2009) to Trp53F/F; PtenF/F 8–10 week old mice. Mice were sacrificed at different time points after the Ad5-cre infection and tumors processed for whole transcriptome analysis. As control animals, Trp53F/F; PtenF/F littermates were used.

2022-08-17 | GSE199905 | GEO

ASCL1 represses a SOX9+ neural-crest-stem-like state in small cell lung cancer

Project description:ASCL1 is a neuroendocrine-lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ~25% of human SCLC are ASCL1-low and associated with low-neuroendocrine fate and high MYC expression. Using genetically-engineered mouse models (GEMMs), we show that alterations in Rb1/Trp53/Myc in the mouse lung induce an ASCL1+ state of SCLC in multiple cells of origin. Genetic depletion of ASCL1 in MYC-driven SCLC dramatically inhibits tumor initiation and progression to the NEUROD1+ subtype of SCLC. Surprisingly, ASCL1 loss promotes a SOX9+ mesenchymal/neural-crest-stem-like state and the emergence of bone and more rarely, cartilaginous tumors. ASCL1 is critical for expression of key lineage-related transcription factors NKX2-1, FOXA2, and INSM1, and represses regulators of Hippo, Wnt and Notch developmental pathways in vivo. ASCL1 also represses SOX9 expression in human SCLC cells, suggesting a conserved function for ASCL1. Here, we utilize single-cell RNA sequencing to capture transcriptomic signatures of RPM (Rb1/Trp53/Myc), RPR2 (Rb1/Trp53/Rbl2), and RPMA (Rb1/Trp53/Myc/Ascl1) GEMM tumors to support our conclusion that in MYC-driven SCLC, ASCL1 promotes neuroendocrine fate and represses the emergence of SOX9+ non-endodermal stem-like or mesenchymal fates. These data were integrated with 4 additional invasive RPM tumors from NCBI GEO: GSE149180.

2021-05-22 | GSE169529 | GEO

Transcriptome profiling of normal and transformed mouse urothelial cells

Project description:Transcriptome analysis of urothelial KRT5-traced and KRT8-traced YFP-sorted cells with and without combinatorial loss of Trp53 and Pten. Bladders from 2-month-old KRT5-CreERT2, Rosa26YFP/LacZ mice, 2-month-old KRT8-CreERT2, Rosa26YFP/LacZ mice, 5-month-old KRT5-CreERT2, p53flox/flox, Ptenflox/flox, Rosa26YFP/+ mice, and 5-month-old KRT8-CreERT2, p53flox/flox, Ptenflox/flox, Rosa26YFP/+ mice were enzymatically dissociated, sorted for YFP by FACS, harvested, resuspended in Trizol and snap frozen for subsequent molecular analysis.

2019-01-01 | GSE110694 | GEO

Molecular subtype classification of urothelial carcinoma in Lynch syndrome

Project description:We aimed to provide a molecular description of Lynch syndrome-associated urothelial cancer in relation to molecular subtypes of sporadic bladder cancer. Whole genome mRNA expression profiles of 41 tumors and immunohistochemical stainings against FGFR3, KRT5, CCNB1, RB1, and CDKN2A (p16) of 37 tumors from Lynch syndrome patients were generated. Pathological data, microsatellite instability, anatomic location, and overall survival data was analyzed and compared with data from sporadic bladder cancer.

2019-01-01 | GSE104922 | GEO

MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate [Bulk RNA-seq of RPM and RPR2 tumors]

Project description:Distinct SCLC molecular subtypes have been defined based on expression of lineage-related transcription factors: ASCL1, NEUROD1, POU2F3 or YAP1, but their origins remain unknown. We perform bulk RNA-sequencing on SCLC tumors from RPM and Rb1/Trp53/Rbl2 (RPR2) GEMMs, initiated by CGRP-Cre, to complement time-series analysis of single-cell transcriptome profiling and reveal that MYC drives the dynamic evolution of SCLC subtypes. MYC promotes a temporal shift from an ASCL1-to-NEUROD1-to-YAP1+ state from a neuroendocrine cell of origin. MYC activates Notch signaling to dedifferentiate tumor cells to non-neuroendocrine fates. Sequenced RPM tumors driven by MycT58A, in comparison to RPR2 tumors associated with high Mycl, have increased intratumoral subtype heterogeneity by bulk-seq, single-cell RNA seq, and IHC compared to RPR2 tumors. In RPM tumors with high MYC, tumors are able to proceed to non-NE subtypes resembling the NEUROD1+ and YAP1+ human SCLC subtypes. These findings support our overall conclusions that genetics, cell of origin, and tumor cell plasticity determine SCLC subtype.

2020-05-28 | GSE149175 | GEO

ASCL1 represses a latent osteogenic program in small cell lung cancer in multiple cells of origin [RNA-Seq]

Project description:ASCL1 is a neuroendocrine-lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ~25% of human SCLC are ASCL1-low and associated with low-neuroendocrine fate and high MYC expression. Using genetically-engineered mouse models (GEMMs), we show that alterations in Rb1/Trp53/Myc in the mouse lung induce an ASCL1+ state of SCLC in multiple cell types. Genetic depletion of ASCL1 in MYC-driven SCLC dramatically inhibits tumor initiation, but surprisingly converts tumors to a SOX9+mesenchymal/neural-crest-stem-like state that has the capacity to differentiate into RUNX2+bone tumors. ASCL1 represses SOX9 expression, as well as WNT and NOTCH developmental pathways, consistent with human gene expression data. SCLC demonstrates remarkable cell fate plasticity with ASCL1 repressing the emergence of non-endodermal stem-like fates that have the capacity for bone differentiation. Here we perform bulk RNA sequencing on RPMA tumor samples to compare gene expression patterrns with RPM tumors with intact ASCL1.

2021-05-22 | GSE155691 | GEO

RNAseq and scRNAseq analysis of UPFL mouse tumors

Project description:Fibroblast growth factor receptor 3 (FGFR3) is altered in up to 50% of urothelial cancers (UC), yet its functional impact is not fully understood. We generated a Cre-inducible FGFR3 S249C allele (LSL-FGFR3 S249C) to understand the functional impact of FGFR3 activation on UC biology, the immune microenvironment, and how FGFR inhibition combines with PD1 immune checkpoint inhibition (ICI). Uroplakin3a (Upk3a) driven expression of Trp53 R270H and FGFR3 S249C (UPFL) promoted tumor formation.

2024-01-01 | GSE217093 | GEO

High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease

Project description:We have developed novel genetically engineered mouse models for high-grade serous carcinoma of the ovary. We compare expression profiles of 4 different models for HGSC, one developing carcinoma from the ovarian surface epithelium (OSE) and 3 others that develop carcinoma from Fallopian tube epithelium (FTE). FTE-originating cancer models utilize either Pax8- or Ovgp1-promotor driven expression of inducible Cre recombinase (CreERT2) and the last model utilizes direct injection of adeno-virus expressing Cre recombinase into oviducts to induce the desired genetic aberrations: loss of Brca1, loss or mutation (R172H) of Trp53 and inhibition of proteins of the Rb family (via expression of K18GT121 transgene). We compare tumors from genetically engineered mouse models (GEMMs) and from GEM-derived allografts and compare them to corresponding normal tissue: ovary or oviduct (mouse equivalent of Fallopian tube). Expression profiling allowed us to investigate molecular subtypes of HGSC in these models and comparison to human HGSC.These well-defined, tractable models represent a valuable resource for assessing novel drugs and immunotherapies for patients with HGSC.

2025-10-31 | GSE299754 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data